BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 12406978)

  • 1. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients.
    Kulpa J; Wójcik E; Reinfuss M; Kołodziejski L
    Clin Chem; 2002 Nov; 48(11):1931-7. PubMed ID: 12406978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP with Clinicopathological Characteristics and Chemotherapeutic Outcomes of Lung Cancer.
    Bi H; Yin L; Fang W; Song S; Wu S; Shen J
    Lab Med; 2023 Jul; 54(4):372-379. PubMed ID: 36282321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of squamous cell carcinoma antigen, carcinoembryonic antigen, Cyfra 21-1 and neuron specific enolase in lung cancer diagnosis: a prospective study from China.
    Song WA; Liu X; Tian XD; Wang W; Liang CY; Zhang T; Guo JT; Peng YH; Zhou NK
    Chin Med J (Engl); 2011 Oct; 124(20):3244-8. PubMed ID: 22088515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
    Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
    Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers in the lung cancer diagnosis: a clinical perspective.
    Li X; Asmitananda T; Gao L; Gai D; Song Z; Zhang Y; Ren H; Yang T; Chen T; Chen M
    Neoplasma; 2012; 59(5):500-7. PubMed ID: 22668014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
    Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions.
    Seemann MD; Beinert T; Fürst H; Fink U
    Lung Cancer; 1999 Dec; 26(3):149-55. PubMed ID: 10598925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [CYFRA 21-1: a new marker of epidermoid cancer of the bronchi. Comparison with 3 other markers].
    Pujol JL; Grenier J; Ray P; Gautier V; Aouta MD; Michel FB
    Presse Med; 1993 Jun; 22(22):1039-42. PubMed ID: 7692432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Cyfra 21-1 as a marker for lung cancer.
    Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R
    Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
    Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
    Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
    Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
    Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
    Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
    J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of serum tumor markers in patients with lung cancer.
    Hatzakis KD; Froudarakis ME; Bouros D; Tzanakis N; Karkavitsas N; Siafakas NM
    Respiration; 2002; 69(1):25-9. PubMed ID: 11844959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
    Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E
    Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer.
    Barlési F; Gimenez C; Torre JP; Doddoli C; Mancini J; Greillier L; Roux F; Kleisbauer JP
    Respir Med; 2004 Apr; 98(4):357-62. PubMed ID: 15080079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients.
    Zhang L; Liu D; Li L; Pu D; Zhou P; Jing Y; Yu H; Wang Y; Zhu Y; He Y; Li Y; Zhao S; Qiu Z; Li W
    BMC Cancer; 2017 Feb; 17(1):96. PubMed ID: 28152979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer.
    Lee JH; Chang JH
    Chest; 2005 Oct; 128(4):2298-303. PubMed ID: 16236887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYFRA 21-1. A new marker in lung cancer.
    Stieber P; Hasholzner U; Bodenmüller H; Nagel D; Sunder-Plassmann L; Dienemann H; Meier W; Fateh-Moghadam A
    Cancer; 1993 Aug; 72(3):707-13. PubMed ID: 7687515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
    Ma S; Shen L; Qian N; Chen K
    Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.